Interleukin-27 tackles immunosuppression in chronic lymphocytic leukemia.
CD8+ T cells
Cytokine
IL-27
immunotherapy
leukemia
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
9
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
epublish
Résumé
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. It is characterized by a high dependency on interactions with the surrounding immune landscape, highlighting its suitability for immune-mediated therapeutic interventions. We recently revealed that the cytokine IL-27 exerts a strong anti-tumor role in CLL through a T-cell-mediated mechanism.
Identifiants
pubmed: 37937211
doi: 10.1080/2162402X.2023.2276490
pii: 2276490
pmc: PMC10627055
doi:
Substances chimiques
Interleukin-27
0
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2276490Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
Eur J Immunol. 2017 Sep;47(9):1562-1572
pubmed: 28688208
Haematologica. 2021 Sep 01;106(9):2312-2324
pubmed: 33882636
Blood. 2018 Apr 5;131(14):1617-1621
pubmed: 29439955
Oncoimmunology. 2018 May 24;7(8):e1465167
pubmed: 30221064
Mediators Inflamm. 2017;2017:3958069
pubmed: 28255204
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
J Interferon Cytokine Res. 2019 Jan;39(1):6-21
pubmed: 29889594
Haematologica. 2023 Nov 01;108(11):3011-3024
pubmed: 37345470
Clin Cancer Res. 2012 Mar 15;18(6):1630-40
pubmed: 22383738